As a PBM, we closely monitor emerging therapies that have the potential to impact patient outcomes, healthcare costs, and benefit plan strategies. One area generating significant attention right now is the growing interest in peptide therapies. Last week, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted in support of adding several injectable peptides – including BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax – to the 503A Bulk Drug Substances list, potentially allowing state-licensed compounding pharmacies to prepare these products in the future.
Peptides are being promoted for a wide range of purposes, including weight management, recovery, wound healing, inflammation, longevity, and metabolic health. Social media, wellness clinics, and direct-to-consumer marketing have fueled tremendous awareness, driving demand well beyond traditional healthcare channels. Many of these compounds remain non-FDA approved, with limited human clinical data available to fully establish their safety and effectiveness. While the committee's recommendation may increase access, it does not represent an FDA determination that these therapies are safe or effective.
For employers, plan sponsors, healthcare providers, and patients, this creates an important conversation regarding:
- Balancing innovation with evidence-based medicine.
- Protecting patient safety while supporting access to emerging therapies.
- Monitoring increases in peptide utilization and the potential to impact healthcare costs and benefit plans.
At ProAct, we believe innovation is critical to advancing healthcare. But innovation should always be accompanied by rigorous clinical evaluation, patient safety oversight, and thoughtful utilization management. The peptide market is evolving rapidly, and additional compounds are already scheduled for FDA advisory review in 2027. As this category continues to expand, healthcare stakeholders will need to navigate a complex landscape of patient demand, clinical evidence, regulatory developments, and cost management. The future of peptide therapy won't be defined by popularity – it will be defined by the evidence.
